Skip to Content
  • Kinases: Hot or Not?

    For the last ten or fifteen years, untold amounts of time and money have been spent developing drugs to inhibit kinase enzymes. Just go take a look at KinasePro… Read More
  • A Long Tail Indeed

    A reader reminded me of this paper, which I meant to blog on when it came out last year. The authors looked over the entire Chemical Abstracts Service registry… Read More
  • Ten Years After: The Genomics Frenzy

    So it’s been ten years now since the peak of the genomics craze in the drug industry. Hard to believe! Looking back on these things, it can be hard to recaptu… Read More
  • Why Pfizer?

    I get occasional comments and e-mails asking why I’m so hard on Pfizer. It’s not that I have anything personal against the company – I’ve never worked t… Read More
  • New Year – I Hope!

    In past years, around this time I’ve often done a look back at the previous year in the drug industry. I hope that no one will be disappointed if I scuttle th… Read More
  • When Placebos Were All There Were

    Yesterday’s discussion of how to deal with various forms of pseudoscientific hoo-hah naturally brought up several mentions of the placebo effect. And that… Read More
  • Curse Of the Lost Compounds

    There are some groups of compounds that seem to have a curse on them. They show up in drug screening, they have activity that’s often too good to ignore, but… Read More
  • Novartis and Reality

    I know that it’s not necessarily fair to drag out old press releases, but let’s do it anyway. Many readers will remember a few years back when Novartis was… Read More
Page 30 of 39« First...1020...2829303132...Last »